US News Pulse Newsroom
Editorial Team
Published : Nov 22, 2026
Online Edition

New Pancreatic Cancer Pill Makes Tumours Vanish in 1 in 12 Patients in Trial

New Pancreatic Cancer Pill Makes Tumours Vanish in 1 in 12 Patients in Trial

A daily pill has made tumours disappear completely in about one in 12 people with advanced pancreatic cancer, according to results from an early trial presented on Friday, November 20, 2026. The drug, daraxonrasib, was given alongside standard chemotherapy to 61 patients whose cancer had already spread and who had not yet received treatment for their advanced disease. Tumours shrank in 60.7 percent of patients and vanished entirely on scans in 8.2 percent, while the treatment stopped tumour growth in 90.2 percent of those taking part. Patients went a median of 12.8 months without their cancer growing, nearly double the time typically seen with standard chemotherapy alone, and 76.6 percent were still alive after one year. The lead researcher called the findings a breakthrough for a disease with few effective treatments, though experts cautioned that the trial was small and had no comparison group.

Key Points

  • Daraxonrasib, a daily oral pill from Revolution Medicines, was tested with standard chemotherapy in 61 patients with advanced pancreatic cancer.
  • Tumours shrank in 60.7 percent of patients and disappeared completely on scans in 8.2 percent, about one in 12.
  • The combination stopped tumour growth in 90.2 percent of participants, and median progression-free survival reached 12.8 months.
  • More than three in four patients, 76.6 percent, were still alive after one year, with a median follow-up of 18 months.
  • Side effects included rash, diarrhoea and fatigue, and 5 percent of patients stopped the drug because of side effects linked to daraxonrasib.

What Happened

The results were presented on Friday, November 20, 2026, at the EORTC-NCI-AACR Symposium in Barcelona. The Phase 1/2 trial enrolled 61 patients with advanced pancreatic cancer that had already spread. None had yet received treatment for their advanced disease. Each patient took daraxonrasib once a day by mouth, together with two standard chemotherapy drugs, gemcitabine and nab-paclitaxel, the usual first treatment for this stage of the disease.

The numbers drew attention because pancreatic cancer is notoriously hard to treat. Tumours shrank in nearly two in three patients, and in five of the 61, tumours could no longer be seen on scans at all. The treatment held the disease in check for 90.2 percent of participants. Patients lived a median of 12.8 months before their cancer started growing again, and with a median follow-up of 18 months, 76.6 percent were still alive at one year. The trial was led by Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, who described the results as a "massive, massive breakthrough" and noted that median progression-free survival had exceeded one year.

Background and Context

Pancreatic cancer is one of the deadliest cancers in the United States. Only about 13 percent of patients are alive five years after diagnosis, according to the American Cancer Society, and most cases are found only after the cancer has spread, when surgery is no longer possible. Standard chemotherapy can slow the disease, but it rarely shrinks tumours for long, and survival gains have been small for decades. That is why a result like this one, with tumours vanishing in some patients, is being watched so closely.

The findings arrive in a year of striking health news in the United States. A Reuters investigation found that measles cases had surged past 7,700 nationwide, with 13 deaths, the highest totals in nearly four decades. Researchers also reported that a blood test may detect chronic traumatic encephalopathy in living patients for the first time, and a federal task force backed HPV testing over the Pap smear for cervical cancer screening. Against that backdrop, a targeted pill that attacks one of cancer's most stubborn drivers is a different kind of advance.

How the Pancreatic Cancer Pill Works

Daraxonrasib targets RAS, a family of growth signals that drive many cancers, and in particular KRAS, the mutated gene found in about 90 percent of pancreatic cancers. KRAS was long considered undruggable because its protein has a smooth surface with almost nowhere for a drug to grip. Daraxonrasib is designed to switch off the faulty signal, cutting the message that tells cancer cells to keep growing and dividing. Because it is a pill taken once a day at home, it is far easier to use than the infusions that dominate cancer care, and it was given here on top of chemotherapy rather than instead of it.

Reactions and Quotes

Dr Park, presenting the data in Barcelona, called the results a "massive, massive breakthrough" and said median progression-free survival had exceeded one year, a milestone that standard chemotherapy alone has rarely reached in this setting. Other experts urged caution alongside the excitement. The trial enrolled only 61 patients, it had a single arm with no control group receiving chemotherapy alone, and it cannot yet prove that patients live longer overall. Side effects were also part of the picture: rash, diarrhoea and fatigue were common, and 5 percent of patients stopped daraxonrasib because of side effects attributed to the drug. Revolution Medicines has already moved to the next stage of testing.

Why It Matters

For patients and families facing pancreatic cancer, the numbers matter because the disease offers so little hope today. A treatment that shrinks tumours in six in ten patients, makes them disappear in one in 12, and nearly doubles the time before the cancer grows again would be a genuine step forward if it survives larger testing. It also matters for cancer research more broadly: KRAS mutations drive large shares of lung and bowel cancers too, so a drug that can switch off RAS could eventually reach far beyond one disease. For now, though, the result is a signal, not a verdict.

What Happens Next

A larger randomised Phase III trial, called RASolute-303, is now under way. It will compare the daraxonrasib combination against standard treatment in a much bigger group of patients, with a control arm the early trial lacked, and test whether the longer time without the cancer growing translates into longer overall survival. Results are not expected quickly. Until then, daraxonrasib remains experimental, available only through clinical trials.

Frequently Asked Questions

What is daraxonrasib?
Daraxonrasib is an experimental daily pill from Revolution Medicines that targets RAS and KRAS growth signals, which drive about 90 percent of pancreatic cancers. It is not yet approved for use outside clinical trials.

How well did the drug work in the trial?
Tumours shrank in 60.7 percent and disappeared completely on scans in 8.2 percent. The treatment stopped tumour growth in 90.2 percent, and median progression-free survival was 12.8 months.

What were the side effects?
The most common side effects were rash, diarrhoea and fatigue. Five percent of patients stopped taking daraxonrasib because of side effects attributed to the drug.

Is the treatment available now?
No. Daraxonrasib is still experimental. A larger randomised Phase III trial, RASolute-303, is under way, and the drug will only be considered for approval after those results are known.

Why is pancreatic cancer so hard to treat?
Most cases are diagnosed after the cancer has spread, when surgery is no longer possible, and only about 13 percent of patients are alive five years after diagnosis, according to the American Cancer Society.

US News Pulse
Written by
US News Pulse Newsroom
Editorial Team

The US News Pulse newsroom covers breaking news across the United States and the world, working from wire services, official statements and on-the-record sources. Every story is reviewed against our editorial standards before publication. Corrections and tips: info@usnewspulse.com

About our newsroom

Leave a Comment

  • Latest
  • Popular

Van Gogh's Chestnut Trees in Blossom Sells for Record $190.4

1

Peter Navarro pide a la Corte Suprema anular sus condenas po

2

Dinamarca acusa a Rusia de un complot para matar al rapero K

3

Irán ataca una instalación industrial civil en Baréin y prov

4

White House Seizes Reporters' Phones on Air Force One After

5

GTA VI Earns Record $3.79 Billion in Day-One Sales, Biggest

6

US Jobless Claims Fall to 189,000, a 57-Year Low, as Layoffs

7

Huawei Trial Ends in Brooklyn as Jury Prepares to Rule on 12

8

La CFTC investigó el memecoin de Trump y abandonó la pesquis

9

Trump, Xi y Putin abren la primera cumbre trilateral de la h

10

Bernie Sanders Vows $2,400 Social Security Boost as Top Prio

11

Susan Smith: Le Niegan la Libertad Condicional por Segunda V

12

Rugby League World Cup: Australia Beat New Zealand 32-12 for

13

Lisa Cook to Boycott 'Unfair' White House Firing Hearing, La

14

Georgia Stays No. 1 as Texas Jumps to No. 5 in College Footb

15

Iran-Linked Assassination Plot in Greece Foiled, Five Suspec

16

LeBron James Passes Jason Kidd for Third on NBA Assists List

17

Los asesinatos caen un 17,3% en las grandes ciudades de EE.

18

Somaliland Detains Five Americans Over Security Fears, Then

19

Omalizumab Eases Red-Meat Allergy in 95% of Alpha-Gal Patien

20